US5733545A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Platelet glue wound sealant
Assignee: QUANTIC BIOMEDICAL Inc
•
Filing: 1996-02-27
•
Granted: 1998-03-31
•
Expires: 2016-02-27
Abstract
Abstract A plasma-buffy coat concentrate that comprises plasma, platelets at a concentration of at least 1.0x109 cells/ml, and fibrinogen at concentration of at least 5 mg/ml is described. The plasma-buffy coat concentrate can be combined with a fibrinogen activator to form a platelet glue wound sealant. A method for processing blood to produce the plasma-buffy coat concentrate is also provided. The method comprises centrifuging anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture. Water is removed from the mixture to produce the plasma-buffy coat concentrate. A fibrinogen activator is mixed with the plasma-buffy coat concentrate to produce a wound sealant, which can then be applied to a wound to facilitate sealing and healing of the wound.
Inventors
- 👤 Andrew G. Hood, III
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:07
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61K35/15; A61K35/17; A61K35/19; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; A61P; A61P17/00; A61P17/02; A61P7/00; A61P7/04
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
40 words
A plasma-buffy coat concentrate comprising: a. plasma; b. platelets at a concentration of at least 1.0×10 9 cells/ml; c. fibrinogen at concentration of at least 5 mg/ml; and d. white cells at a concentration of at least 3.0×10 7 cells/ml.
Claim 2
Dependent Claim
40 words
A plasma-buffy coat concentrate comprising: a. plasma; b. platelets at a concentration of at least 1.0×10 9 cells/ml; c. fibrinogen at concentration of at least 5 mg/ml; and d. white cells at a concentration of at least 3.0×10 7 cells/ml.
Claim 3
Dependent Claim
21 words
The plasma-buffy coat concentrate of claim 1 wherein platelet concentration is from about 1.0×10 9 cells/ml to about 2.5×10 9 cells/ml.
Claim 4
Dependent Claim
19 words
The plasma-buffy coat concentrate of claim 1 wherein the fibrinogen concentration is from about 5 to about 15 mg/ml.
Claim 5
Dependent Claim
22 words
The plasma-buffy coat concentrate of claim 1 wherein white cell concentration is from about 3.0×10 7 cells/ml to about 6.0×10 7 cells/ml.
Claim 6
Dependent Claim
31 words
The plasma-buffy coat concentrate of claim 4 wherein the white cells comprise about 60 to about 70% lymphocytes, about 15 to about 25% monocytes, and about 5 to about 25% neutrophils.
Claim 7
Dependent Claim
51 words
A wound sealant comprising: a plasma; b. platelets at a concentration of at least 1.0×10 9 cells/ml; c. fibrinogen at concentration of at least 5 mg/ml; d. white cells at a concentration of at least 3.0×10 7 cells/ml; and e. a fibrinogen activator in a concentration sufficient to initiate clot formation.
Claim 8
Dependent Claim
51 words
A wound sealant comprising: a plasma; b. platelets at a concentration of at least 1.0×10 9 cells/ml; c. fibrinogen at concentration of at least 5 mg/ml; d. white cells at a concentration of at least 3.0×10 7 cells/ml; and e. a fibrinogen activator in a concentration sufficient to initiate clot formation.
Claim 9
Dependent Claim
20 words
The wound sealant of claim 6 wherein the fibrinogen activator is selected from the group consisting of thrombin and batroxobin.
Claim 10
Dependent Claim
12 words
The wound sealant of claim 7 wherein the fibrinogen activator is thrombin.
Claim 11
Dependent Claim
22 words
The wound sealant of claim 8 wherein the thrombin is produced from prothrombin present in the plasma component of the wound sealant.
Claim 12
Independent Claim
41 words
A method for processing blood comprising: a. centrifugally fractionating anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture; and b. hemoconcentrating the plasma-buffy coat mixture to remove water from the mixture to produce a plasma-buffy coat concentrate.
Claim 13
Independent Claim
41 words
A method for processing blood comprising: a. centrifugally fractionating anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture; and b. hemoconcentrating the plasma-buffy coat mixture to remove water from the mixture to produce a plasma-buffy coat concentrate.
Claim 14
Dependent Claim
21 words
The method of claim 10 further comprising mixing the plasma-buffy coat concentrate with a fibrinogen activator to produce a wound sealant.
Claim 15
Dependent Claim
14 words
The method of claim 11 further comprising applying the wound sealant to a wound.
Claim 16
Dependent Claim
11 words
The method of claim 10 wherein the blood is processed peri-operatively.
Claim 17
Dependent Claim
30 words
The method of claim 10 wherein the volume of water removed from the plasma in about (b) is between about 50 and about 75 percent of the original plasma volume.
Claim 18
Dependent Claim
25 words
The method of claim 10 wherein the leukocyte concentration of the plasma-buffy coat concentrate is at least five times the leukocyte concentration of the blood.
Claim 19
Dependent Claim
28 words
The method of claim 15 wherein the lymphocyte, monocyte, and platelet concentrations of the plasma-buffy coat concentrate are at least ten times the respective concentrations of the blood.
Claim 20
Independent Claim
66 words
A method of promoting wound sealing comprising: a. centrifugally fractionating anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture; b. hemoconcentrating the plasma-buffy coat mixture to remove water from the mixture to produce a plasma-buffy coat concentrate; c. mixing the plasma-buffy coat concentrate with a fibrinogen activator to produce a wound sealant; and d. applying the wound sealant to a damaged tissue.
Claim 21
Independent Claim
66 words
A method of promoting wound sealing comprising: a. centrifugally fractionating anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture; b. hemoconcentrating the plasma-buffy coat mixture to remove water from the mixture to produce a plasma-buffy coat concentrate; c. mixing the plasma-buffy coat concentrate with a fibrinogen activator to produce a wound sealant; and d. applying the wound sealant to a damaged tissue.
Claim 22
Dependent Claim
13 words
The method of claim 17 wherein the blood and the tissue are human.
Claim 23
Dependent Claim
16 words
The method of claim 17 wherein the blood and the tissue are from the same animal.
References Cited (Backward Citations)
US4004975A
Cited
US4159896A
Cited
US4362567A
Cited
US4343793A
Cited
US4359049A
Cited
EP0068048A2
Cited
US4427650A
Cited
EP0068047A2
Cited
US4631055A
Cited
US4627879A
Cited
US5165938A
Cited
WO1986003122A1
Cited
US4735616A
Cited
WO1988002259A1
Cited
US5318782A
Cited
US4978336A
Cited
US5290552A
Cited
US4902281A
Cited
US5428008A
Cited
US5405607A
Cited
WO1991000046A2
Cited
WO1991009573A1
Cited
US5185001A
Cited
EP0446713A2
Cited
US5039401A
Cited
US5304372A
Cited
US5330974A
Cited
US5437598A
Cited
US5585007A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-30 | 2001-09-29 | 2002-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-30 | 2005-09-29 | 2006-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-30 | 2009-09-29 | 2010-03-31 | $7700.00 | Window Closed / Lapsed |